(Q34633457)

3 August 2017

1 reference

title

Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir (English)

1 reference

3 August 2017

1 reference

1 reference

1 reference

2

Angela D M Kashuba

1 reference

3 August 2017

Manoli Vourvahis

1

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 June 2007

1 reference

3 August 2017

1 reference

3 August 2017

volume

27

1 reference

3 August 2017

issue

6

1 reference

3 August 2017

page(s)

888-909

1 reference

Tipranavir: A Protease Inhibitor From a New Class With Distinct Antiviral Activity

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Tipranavir (PNU-140690): A Potent, Orally Bioavailable Nonpeptidic HIV Protease Inhibitor of the 5,6-Dihydro-4-hydroxy-2-pyrone Sulfonamide Class∇

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

A 14-day dose-response study of the efficacy, safety, and pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Tipranavir: a ritonavir-boosted protease inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

The effect of intravenous and oral fluconazole on the pharmacokinetics and pharmacodynamics of intravenous alfentanil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Effect of itraconazole on the pharmacokinetics and pharmacodynamics of a single oral dose of brotizolam

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Interaction of common azole antifungals with P glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Ketoconazole and lopinavir/ritonavir coadministration: boosting beyond boosting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Identification of the Cytochrome P450 Enzymes Involved in theN-Oxidation of Voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

No clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Tuberculosis and HIV/AIDS: epidemiological and clinical aspects (world perspective).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Pharmacokinetic interaction between rifampin and the combination of indinavir and low-dose ritonavir in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study G

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Efficacy and safety of atorvastatin in the treatment of hypercholesterolemia associated with antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Enteric infections and diarrhea in human immunodeficiency virus-infected persons: prospective community-based cohort study. Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

The evaluation and application of a radioimmunoassay for the measurement of diphenoxylic acid, the major metabolite of diphenoxylate hydrochloride (Lomotil), in human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Blockade of HERG channels by HIV protease inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Amiodarone N-deethylation in human liver microsomes: involvement of cytochrome P450 3A enzymes (first report).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Usefulness of hepatocytes for evaluating the genetic polymorphism of CYP2D6 substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Electrophysiology and pharmacology of ibutilide

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

The early use of ergotamine in migraine. Edward Woakes' report of 1868, its theoretical and practical background and its international reception

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Irreversible coma, ergotamine, and ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Long QT syndrome during high-dose cisapride

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

High affinity blockade of the HERG cardiac K(+) channel by the neuroleptic pimozide

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Interaction between grapefruit juice and diazepam in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

A potentially hazardous interaction between erythromycin and midazolam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

First-pass metabolism of midazolam by the human intestine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Differential impairment of triazolam and zolpidem clearance by ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

High prevalence of insomnia in an outpatient population with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Zaleplon: a review of its use in the treatment of insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Inhibition of zaleplon metabolism by cimetidine in the human liver: in vitro studies with subcellular fractions and precision-cut liver slices

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Metabolism of Zaleplon by human hepatic microsomal cytochrome P450 isoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Outcome of Hepatitis B Virus Infection in Homosexual Men and Its Relation to Prior Human Immunodeficiency Virus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Hepatitis C virus infection in patients infected with the human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Prevalence of Antibody to Hepatitis C Virus in Patients Infected with the Human Immunodeficiency Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Kidney transplantation in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Tacrolimus and lopinavir/ritonavir interaction in liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Sirolimus and ketoconazole co-prescription in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Drug concentration monitoring of immunosuppressive agents: focus on tacrolimus, mycophenolate mofetil and sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Nefazodone Inhibits Methylprednisolone Disposition and Enhances its Adrenal-Suppressant Effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Impact of ketoconazole on the metabolism of prednisolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Ritonavir's role in reducing fentanyl clearance and prolonging its half-life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Comparative biotransformation of morphine, codeine and pholcodine in rat hepatocytes: identification of a novel metabolite of pholcodine

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Increased CNS uptake and enhanced antinociception of morphine-6-glucuronide in rats after inhibition of P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Evidence for P-glycoprotein-modulated penetration of morphine-6-glucuronide into brain capillary endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Meta-analysis of the relationship between HIV infection and risk for depressive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Temporal trends in the incidence of HIV-1-related neurologic diseases: Multicenter AIDS Cohort Study, 1985-1992.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Neurologic manifestations of HIV infection. Using imaging studies and antiviral therapy effectively

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Seizures in human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

New-onset seizures associated with human immunodeficiency virus infection: causation and clinical features in 100 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Carbamazepine--indinavir interaction causes antiretroviral therapy failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9)

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Functional induction and de-induction of P-glycoprotein by St. John's wort and its ingredients in a human colon adenocarcinoma cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

St Johns wort increases expression of P-glycoprotein: implications for drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Indinavir concentrations and St John's wort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Impact of acid-suppressive therapy on virologic response to atazanavir-based regimens in antiretroviral-experienced patients: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

Pharmacology of itraconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.6.888

21 January 2018

Identifiers

DOI

10.1592/PHCO.27.6.888

1 reference

3 August 2017

1 reference